Anti-SARS-CoV S Recombinant Antibody (CR3022) (CAT#: MRO-1214LC)

Figure 1 Neutralization of Wild-Type SARS-CoV and a CR3014-Neutralization Escape Variant (E6) with mAbs CR3014 and CR3022 Individually and in Combination.

Neutralization of 100 TCID ₅₀ of each virus was performed in octuplicate.

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

Figure 2 Binding of mAbs CR3014 and CR3022 to Recombinant Wild-Type and P462L-Substituted S318–510 Fragments Analyzed by ELISA.

Bars represent the means ± standard deviation.

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

Figure 3 Competition ELISA on Immobilized S318–510.

Binding of biotinylated CR3022 was analyzed in the presence of competitor CR3014 (open circles), CR3022 (closed circles), and control mAb (open squares). Binding is expressed as percentage of binding without competitor.

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

Figure 1 Anti-SARS-CoV S Therapeutic Antibody (CR3022) (MRO-1214LC) in WB

Western blot analysis of MRO-1214LC was performed with Human SARS Coronavirus Spike Protein (S1 Subunit, His Tag).
MRO-1214LC incubation concentration: 1.25ng/μL.
The secondary antibody: HRP Goat Anti-Human IgG (H+L)
Lane 1: Reducing Antigen (0.1μg)
Lane 2: Reducing Antigen (0.3μg)
Lane 3: Reducing Antigen (0.6μg)

Figure 2 Anti-SARS-CoV S Therapeutic Antibody (CR3022) (MRO-1214LC) in WB

Western blot analysis of MRO-1214LC was performed with SARS-CoV-2 Spike Protein (RBD, his Tag).
MRO-1214LC incubation concentration: 2ng/μL.
The secondary antibody: HRP Goat Anti-Human IgG (H+L)
Lane 1: Reducing Antigen (0.1μg)
Lane 2: Reducing Antigen (0.5μg)
Lane 3: Reducing Antigen (1μg)

Figure 3 Anti-SARS-CoV S Therapeutic Antibody (CR3022) (MRO-1214LC) in ELISA

ELISA analysis of MRO-1214LC was performed by coating with SARS-CoV-2 Spike Protein (RBD, his Tag).
The secondary antibody: HRP Goat Anti-Human IgG (H+L)

Figure 4 Anti-SARS-CoV S Therapeutic Antibody (CR3022) (MRO-1214LC) in ELISA

ELISA analysis of MRO-1214LC was performed by coating with Human SARS Coronavirus Spike Protein (S1 Subunit, His Tag).
The secondary antibody: HRP Goat Anti-Human IgG (H+L)

Figure 5 Anti-SARS-CoV S Therapeutic Antibody (CR3022) (MRO-1214LC) in Dot Blot

Dot Blot analysis of MRO-1214LC was performed with SARS-CoV-2 Spike Protein (RBD, his Tag).
MRO-1214LC incubation concentration: 1.25ng/μL.
The secondary antibody: HRP Goat Anti-Human IgG (H+L)

Figure 6 Anti-SARS-CoV S Therapeutic Antibody (CR3022) (MRO-1214LC) in Dot Blot

Dot Blot analysis of MRO-1214LC was performed with Human SARS Coronavirus Spike Protein (S1 Subunit, His Tag).
MRO-1214LC incubation concentration: 1.25ng/μL.
The secondary antibody: HRP Goat Anti-Human IgG (H+L)